Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 5/20 | 0.44 |
| ▸ | RAB9A | P51151 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PHGDH | O43175 | 3/20 | 0.43 |
| ▸ | ACACB | O00763 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21378588 | 1.00 | TP53 (0.46) | TP53NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL21378555 | 0.89 | NPC1 (0.52) | TP53NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL21378557 | 0.89 | NPC1 (0.52) | TP53NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL21378505 | 0.84 | PHGDH (0.55) | TP53NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL21378508 | 0.84 | PHGDH (0.55) | TP53NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL21396337 | 0.83 | MAPT (0.62) | TP53NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL21378434 | 0.82 | TP53 (0.49) | TP53NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL21378435 | 0.82 | TP53 (0.49) | TP53NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL21378462 | 0.80 | TP53 (0.56) | TP53NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL21378466 | 0.80 | TP53 (0.56) | TP53NPC1RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11370758-B2 | IDO-TDO dual inhibitor and related methods of use | CMG PHARMACEUTICAL CO., LTD. (KR) | 2022-06-28 | — | — | US | disclosed |
| US-20190292150-A1 | IDO-TDO DUAL INHIBITOR AND RELATED METHODS OF USE | CMG PHARMACEUTICAL CO., LTD. (KR) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292150-A1 | IDO-TDO DUAL INHIBITOR AND RELATED METHODS OF USE | IDO1, IDO2, TDO2 | TP53 4040/4885NPC1 2627/4885RAB9A 2763/4885 |
| US-11370758-B2 | IDO-TDO dual inhibitor and related methods of use | IDO1, IDO2, TDO2 | TP53 4040/4885NPC1 2627/4885RAB9A 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.